Candida albicans versus non-albicans bloodstream infections: The comparison of risk factors and outcome

Journal of Microbiology, Immunology and Infection

Volumn 44, Issue 5, 2011, Pages 369-375

  Chi, Hung Wei ^a,b   Yang, Ya Sung ^b   Shang, Shi Ta ^a,b   Chen, Ke Hung ^a,b   Yeh, Kuo Ming ^b   Chang, Feng Yee ^b   Lin, Jung Chung ^b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

Candida albicans; Candidemia; Non albicans

Indexed keywords

FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; VORICONAZOLE;

ADULT; AGED; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA HAEMONULONII; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDEMIA; CANDIDURIA; FATALITY; FEMALE; HUMAN; INFECTION RISK; INTENSIVE CARE; KIDNEY FUNCTION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NEUTROPENIA; NONHUMAN; PROGNOSIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; SHOCK;

ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; CANDIDA; CANDIDEMIA; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; TAIWAN; TREATMENT OUTCOME;

EID: 80053648396     PISSN: 16841182     EISSN: 19959133     Source Type: Journal    
DOI: 10.1016/j.jmii.2010.08.010     Document Type: Article

References (38)

1. Jarvis W.R. Epidemiology of nosocomial fungal infections, with emphasis on Candida species. Clin Infect Dis 1995, 20:1526-1530.
2. Chen Y.C., Chang S.C., Sun C.C., Yang L.S., Hsieh W.C., Luh K.T. Secular trends in the epidemiology of nosocomial fungal infections at a teaching hospital in Taiwan, 1981 to 1993. Infect Control Hosp Epidemiol 1997, 18:369-375.
3. Asmundsdottir L.R., Erlendsdottir H., Gottfredsson M. Increasing incidence of candidemia: results from a 20-year nationwide study in Iceland. J Clin Microbiol 2002, 40:3489-3492.
4. Hsueh P.R., Chen M.L., Sun C.C., Chen W.H., Pan H.J., Yang L.S., et al. Antimicrobial drug resistance in pathogens causing nosocomial infections at a university hospital in Taiwan, 1981-1999. Emerg Infect Dis 2002, 8:63-68.
5. Viscoli C., Girmenia C., Marinus A., Collette L., Martino P., Vandercam B., et al. Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis 1999, 28:1071-1079.
6. Trick W.E., Fridkin S.K., Edwards J.R., Hajjeh R.A., Gaynes R.P. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis 2002, 35:627-630.
7. Chow J.K., Golan Y., Ruthazer R., Karchmer A.W., Carmeli Y., Lichtenberg D., et al. Factors associated with candidemia caused by non-albicans Candida species versus Candida albicans in the intensive care unit. Clin Infect Dis 2008, 46:1206-1213.
8. Colombo A.L., Nucci M., Salomao R., Branchini M.L., Richtmann R., Derossi A., et al. High rate of non-albicans candidemia in Brazilian tertiary care hospitals. Diagn Microbiol Infect Dis 1999, 34:281-286.
9. Dimopoulos G., Ntziora F., Rachiotis G., Armaganidis A., Falagas M.E. Candida albicans versus non-albicans intensive care unit-acquired bloodstream infections: differences in risk factors and outcome. Anesth Analg 2008, 106:523-529.
10. Pfaller M.A., Jones R.N., Doern G.V., Sader H.S., Hollis R.J., Messer S.A. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada, and South America for the SENTRY Program. The SENTRY Participant Group. J Clin Microbiol 1998, 36:1886-1889.
11. Tortorano A.M., Peman J., Bernhardt H., Klingspor L., Kibbler C.C., Faure O., et al. Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis 2004, 23:317-322.
12. Morrell M., Fraser V.J., Kollef M.H. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for ospital mortality. Antimicrob Agents Chemother 2005, 49:3640-3645.
13. Hung C.C., Chen Y.C., Chang S.C., Luh K.T., Hsieh W.C. Nosocomial candidemia in a university hospital in Taiwan. J Formos Med Assoc 1996, 95:19-28.
14. Cheng M.F., Yu K.W., Tang R.B., Fan Y.H., Yang Y.L., Hsieh K.S., et al. Distribution and antifungal susceptibility of Candida species causing candidemia from 1996 to 1999. Diagn Microbiol Infect Dis 2004, 48:33-37.
15. Pfaller M.A., Messer S.A., Boyken L., Hollis R.J., Rice C., Tendolkar S., et al. In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. Diagn Microbiol Infect Dis 2004, 48:201-205.
16. Yang Y.L., Ho Y.A., Cheng H.H., Ho M., Lo H.J. Susceptibilities of Candida species to amphotericin B and fluconazole: the emergence of fluconazole resistance in Candida tropicalis. Infect Control Hosp Epidemiol 2004, 25:60-64.
17. Nguyen M.H., Clancy C.J., Yu V.L., Yu Y.C., Morris A.J., Snydman D.R., et al. Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia. J Infect Dis 1998, 177:425-430.
18. Pfaller M.A., Diekema D.J., Rex J.H., Espinel-Ingroff A., Johnson E.M., Andes D., et al. Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J Clin Microbiol 2006, 44:819-826.
19. Pfaller M.A., Boyken L., Hollis R.J., Kroeger J., Messer S.A., Tendolkar S., et al. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol 2008, 46:150-156.
20. Pfaller M.A., Diekema D.J., Jones R.N., Sader H.S., Fluit A.C., Hollis R.J., et al. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J Clin Microbiol 2001, 39:3254-3259.
21. Wang J.L., Chang S.C., Hsueh P.R., Chen Y.C. Species distribution and fluconazole susceptibility of Candida clinical isolates in a medical center in 2002. J Microbiol Immunol Infect 2004, 37:236-241.
22. Cheng Y.R., Lin L.C., Young T.G., Liu C.E., Chen C.H., Tsay R.W. Risk factors for candidemia-related mortality at a medical center in central Taiwan. J Microbiol Immunol Infect 2006, 39:155-161.
23. Bader M.S., Lai S.M., Kumar V., Hinthorn D. Candidemia in patients with diabetes mellitus: epidemiology and predictors of mortality. Scand J Infect Dis 2004, 36:860-864.
24. Nguyen M.H., Peacock J.E., Morris A.J., Tanner D.C., Nguyen M.L., Snydman D.R., et al. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med 1996, 100:617-623.
25. Redding S.W., Kirkpatrick W.R., Dib O., Fothergill A.W., Rinaldi M.G., Patterson T.F. The epidemiology of non-albicans Candida in oropharyngeal candidiasis in HIV patients. Spec Care Dentist 2000, 20:178-181.
26. Wingard J.R. Importance of Candida species other than C. albicans as pathogens in oncology patients. Clin Infect Dis 1995, 20:115-125.
27. Abi-Said D., Anaissie E., Uzun O., Raad I., Pinzcowski H., Vartivarian S. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 1997, 24:1122-1128.
28. Cheng M.F., Yang Y.L., Yao T.J., Lin C.Y., Liu J.S., Tang R.B., et al. Risk factors for fatal candidemia caused by Candida albicans and non-albicans Candida species. BMC Infect Dis 2005, 5:22.
29. Nikawa H., Egusa H., Makihira S., Nishimura M., Ishida K., Furukawa M., et al. A novel technique to evaluate the adhesion of Candida species to gingival epithelial cells. Mycoses 2003, 46:384-389.
30. Viudes A., Peman J., Canton E., Ubeda P., Lopez-Ribot J.L., Gobernado M. Candidemia at a tertiary-care hospital: epidemiology, treatment, clinical outcome and risk factors for death. Eur J Clin Microbiol Infect Dis 2002, 21:767-774.
31. Antoniadou A., Torres H.A., Lewis R.E., Thornby J., Bodey G.P., Tarrand J.P., et al. Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy. Medicine (Baltimore) 2003, 82:309-321.
32. Pappas P.G., Rex J.H., Lee J., Hamill R.J., Larsen R.A., Powderly W., et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 2003, 37:634-643.
33. Wisplinghoff H., Bischoff T., Tallent S.M., Seifert H., Wenzel R.P., Edmond M.B. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004, 39:309-317.
34. Kullberg B.J., Sobel J.D., Ruhnke M., Pappas P.G., Viscoli C., Rex J.H., et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 2005, 366:1435-1442.
35. Kontoyiannis D.P., Vaziri I., Hanna H.A., Boktour M., Thornby J., Hachem R., et al. Risk factors for Candida tropicalis fungemia in patients with cancer. Clin Infect Dis 2001, 33:1676-1681.
36. Krcmery V., Barnes A.J. Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance. J Hosp Infect 2002, 50:243-260.
37. Tsai C.C., Wang C.C., Kuo H.Y., Chiang D.H., Lin M.L., Liu C.Y., et al. Adult candidemia at a medical center in northern Taiwan: a retrospective study. J Microbiol Immunol Infect 2008, 41:414-421.
38. Nguyen M.H., Peacock J.E., Tanner D.C., Morris A.J., Nguyen M.L., Snydman D.R., et al. Therapeutic approaches in patients with candidemia. Evaluation in a multicenter, prospective, observational study. Arch Intern Med 1995, 155:2429-2435.